Credit Suisse Worldwide

Search


Sprout Group is one of the oldest and largest institutional venture capital firms focused on emerging companies. Since its founding in 1969, Sprout Group has financed more than 350 companies and has raised nearly $3.0 billion in committed capital from leading institutional investors and individuals. In November 2000, Sprout Group closed Sprout IX, a fund totaling $1.1 billion.

While Sprout IX's new investment phase has been completed and the fund's activities are confined to follow-on investments in existing portfolio companies, we are still interested in new investment opportunities for our associated funds:

New Leaf Venture Partners is actively seeking opportunities in the healthcare technology sector; its focus is primarily on a later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

Contact New Leaf Venture Partners at:

info@nlvpartners.com
(646)871-6400


DLJ Merchant Banking Partners, which focuses on a broad range of buyout opportunities in the $20 million to $250 million range as either the lead or co-lead.

Contact DLJ MBP at:

Steve Rattner
Managing Director
(212)538-0644
Recent News >>
Aspreva Pharmaceuticals Announces Pricing of Initial Public Offering at US$11.00 (C$13.68) per Share
TA Associates Completes Minority Investment in Microban International
Adeza Biomedical Corporation Announces Initial Public Offering of Common Stock
Sprout Group Announces $12M Financing in Sopherion Therapeutics
Workstream Completes Acquisition of Bravanta to Strengthen Compensation Offerings

 




HOME  |  IMPORTANT LEGAL INFORMATION


This page was last updated
Copyright © 2002- Sprout Group. All rights reserved.